Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;36:303-307

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pockley, A. G.
Right arrow Articles by Frostegård, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pockley, A. G.
Right arrow Articles by Frostegård, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Pathophysiology
Right arrow Other hypertension
Right arrow Other arteriosclerosis
Right arrow Mechanism of atherosclerosis/growth factors
Right arrow Other Vascular biology
Right arrow Other Research

(Hypertension. 2000;36:303.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Circulating Heat Shock Protein 60 Is Associated With Early Cardiovascular Disease

A. Graham Pockley; Ruhia Wu; Carola Lemne; Rolf Kiessling; Ulf de Faire; Johan Frostegård

From the Division of Clinical Sciences (NGH) (A.G.P.), Northern General Hospital, Herries Road, Sheffield, UK; and Department of Medicine (R.W., J.F.), Units of Rheumatology and CMM and of Cardiovascular Medicine (C.L., U. de F.), Karolinska Hospital, and Department of Medicine (R.K.), Department of Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.

Correspondence to Graham Pockley, PhD, Division of Clinical Sciences (NGH), Clinical Sciences Centre, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK. E-mail g.pockley{at}sheffield.ac.uk or to Johan Frostegård, MD, Department of Medicine, Unit of Rheumatology and CMM, Karolinska Hospital, 17176 Stockholm, Sweden.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—The phylogenetically conserved nature of heat shock proteins (Hsp) has led to the proposition that they may provide a link between infection and the inflammatory component to vascular disease. Hypertension is associated with atherosclerosis. Here, we measured circulating heat shock protein and heat shock protein antibody levels in association with borderline hypertension. Seventy-two men with borderline hypertension patients and 75 normotensive control subjects (diastolic blood pressure 85 to 94 and <80 mm Hg, respectively) were selected from a population-screening program. The levels of Hsp60; Hsp70; and anti–human Hsp60, anti–human Hsp70, and anti–mycobacterial Hsp65 antibodies were determined with enzyme immunoassay. The presence of carotid atherosclerosis and the intima-media thickness values were determined with ultrasonography. A major novel observation in this report was the detection of circulating Hsp60, which was present at a significantly enhanced level in patients with borderline hypertension. Furthermore, serum Hsp60 was associated with intima-media thicknesses (P<0.01). Anti-Hsp65 antibody levels were higher in borderline hypertension (P<0.001), whereas Hsp70 and anti-Hsp70 antibody levels did not differ. In contrast to anti-Hsp65 antibody, anti-Hsp60 antibody levels were lower in borderline hypertension (P<0.03), although the difference was quantitatively small. None of the parameters evaluated were associated with atherosclerosis, metabolic factors, or smoking. We identified elevated Hsp60 levels in patients with borderline hypertension and an association between early atherosclerosis and Hsp60 levels. The physiological role of Hsp60 release has yet to be defined, but given the proinflammatory properties, these proteins could be involved in the induction/progression of both hypertension and atherosclerosis, as well as being markers for early cardiovascular disease.


Key Words: heat shock proteins • hypertension, borderline • atherosclerosis • human


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Evidence is accumulating that suggests the immunological component to the development of atherosclerosis may, at least in part, involve the expression of and reactivity to heat shock proteins.1 In addition to being constitutively expressed, heat shock proteins are induced in response to a number of biological and physicochemical agents.2 They are involved in repair processes and the intracellular assembly, folding, and translocation of oligomeric proteins.3 The highly conserved nature of heat shock proteins has led to the proposition that there is a link between immune responses to infection and the development of autoimmunity.4 Evidence for the involvement of heat shock proteins in vascular disease has arisen from studies that reported elevated levels of Hsp65 antibodies in patients with carotid atherosclerosis,5 coronary heart disease,6 or borderline hypertension (BHT).7

Although heat shock proteins are typically regarded as being intracellular, they can be expressed on the surface of mononuclear cells8 9 and stressed aortic endothelial cells.10 They can also be released from cultured rat glial and human islet cells,11 12 and Hsp60 and Hsp70 have been identified in the serum of healthy individuals.13 14 Given the potential involvement of heat shock proteins in the pathogenesis of vascular disease and the association between hypertension and atherosclerosis,15 we determined the levels of circulating Hsp60; Hsp70; and anti–human Hsp60, anti–human Hsp70, and anti–mycobacterial 65-kDa protein antibodies in normotensive (NT) and BHT subjects. We make the novel observation that circulating levels of Hsp60 are increased in BHT subjects.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Study Groups
The study groups and their recruitment have been described previously.7 16 Samples from 72 men with BHT (defined as a diastolic blood pressure [DBP] of 85 to 94 mm Hg) and 75 age-matched NT control subjects from the original population were used in the present study. The BP of the control subjects was measured on 2 occasions a few weeks apart. For participation in the study, DBP had to be <=80 mm Hg on both occasions. BP measurements were made by the same nurse.

The study was approved by the local ethics committee of the Karolinska Hospital and was conducted in accordance with the Helsinki Declaration. All subjects gave informed consent.

Study Program
All subjects were investigated according to the same schedule.7 BHT patients and their NT counterparts were assessed simultaneously whenever possible or no more than 4 weeks apart. Blood samples were taken after the participant rested for 15 minutes in the supine position between 8:00 AM and 9:30 AM after a fast of 8 to 12 hours.

Analysis of Total Serum Immunoglobulin Levels
Serum IgG, IgM, and IgA levels were determined with immunoturbidometry (Hitachi 911 analyzer) with anti-IgG, anti-IgM, and anti-IgA reagents and calibrators (DAKO).

Serum Hsp60 and Hsp70 levels
Serum Hsp60 and Hsp70 levels were determined with immunoassay.13 14 Briefly, 96-well microtitre plates (Nunc Immunoplate Maxisorp; Life Technologies) were coated through overnight incubation at 4°C with murine monoclonal antibodies to human Hsp60 (clone LK.1.) or Hsp70 (clone C92F3A-5; StressGen) in carbonate buffer, pH 9.5 (2 µg/mL). Plates were washed with PBS containing 1% vol/vol Tween 20 (PBS/T) and blocked by incubation with 1% wt/vol bovine serum albumin in PBS/T.

Serum samples were added, and bound heat shock protein was detected by the addition of rabbit polyclonal anti-Hsp60 or anti-Hsp70 antibody (1:1000; SPA-804 and SPA-812; StressGen). Bound polyclonal antibody was detected with alkaline phosphatase-conjugated murine monoclonal antibody to rabbit immunoglobulins (Sigma Chemical Co), followed by p-nitrophenyl phosphate substrate (Sigma Chemical Co). The resultant absorbance was measured at 405 nm with a Titertek Multiscan MCC/340 plate reader. Standard dose-response curves were generated in parallel with recombinant human Hsp60 (0 to 2500 ng/mL) or Hsp70 (0 to 20 000 ng/mL; StressGen), and the concentrations of Hsp60 and Hsp70 were determined by reference to these standard curves with ASSAYZAP data analysis software (BIOSOFT). The interassay variability of the Hsp60 and Hsp70 immunoassays was <10%.13 14

Serum Anti–Heat Shock Protein Antibody Levels
Heat shock protein antibody levels were also determined as described previously.13 14 17 Microtiter plates were coated with recombinant human Hsp60 (StressGen), recombinant human Hsp70 (StressGen), or recombinant Mycobacterium bovis Hsp65 (100 µL, 2 µg/mL). M. bovis Hsp65 was provided by the UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (Braunschweig, Germany).

Plates were washed, and nonspecific binding sites were blocked. Serum samples (typically 1:100 in PBS/T) were added, and bound antibodies were detected with alkaline phosphatase conjugated polyclonal goat anti-human IgA/G/M (Sigma Chemical Co) followed by p-nitrophenyl phosphate substrate substrate. Antibody concentrations were determined by comparison with a standard curve that was generated with samples of predetermined high levels that had been assigned a concentration of 1000 arbitrary units/mL (AU/mL).

Plasma Lipoprotein and Insulin Levels
Serum VLDL-, LDL-, and HDL-cholesterol and triglyceride levels were determined as described previously.7 The major plasma lipoprotein fractions were determined with preparative ultracentrifugation and lipid analyses of the lipoprotein fractions.18 Venous blood samples were also taken for the determination of blood glucose (Kodak Ectachem) and plasma insulin (radioimmunoassay; Kabi Pharmacia) levels.

Carotid Ultrasonography
The right and left carotid arteries were examined with a duplex scanner (Acuson 128XP/5) with a 7.0-MHz linear-array transducer. Subjects were investigated in the supine position with the head turned slightly away from the sonographer. The intima-media (I/M) thickness was determined as described previously.15 Plaque was defined as localized I/M thickening, with a thickness of >1 mm and a 100% increase in thickness compared with normal, adjacent wall segments; it was scored as being present or absent.7 The common, internal, and external carotid arteries on both sides were screened.

Statistical Methods
Variables were tested for skewness and groups with skewed variables were compared by the nonparametric Mann-Whitney U test. The Student’s t test was used for the comparison of normally distributed data. Categorical variables were compared by the {chi}2 test. The Spearman rank correlation was used to assess interrelationships among heat shock proteins, heat shock protein antibodies, metabolic variables, and BP levels. Nonnormally distributed variables were logarithmically transformed. Data are presented as mean±SEM for normally distributed data and as median and first and third quartile (Q25 and Q75) values for nonnormally distributed data. The level of statistical significance was set at a value of P<0.05.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Characteristics of Patients and Control Subjects
The characteristics of the 2 study groups are presented in Table 1. The mean BP level for the NT group was 125/75 (±11/5) mm Hg compared with 141/89 (±10/2) mm Hg for the BHT group. The BHT group also had a significantly higher body mass index and waist/hip ratio (Table 1).


View this table:
[in this window]
[in a new window]
 
Table 1. Basic Characteristics of the Study Groups

BHT men had a significantly altered metabolic profile with fasting hyperinsulinemia and dyslipoproteinemia (Table 1), as has been reported previously.19 In the BHT group, 26% of the subjects had detectable carotid plaques on 1 or both sides, whereas the incidence in the NT group was 16% (19 versus 10 subjects, NS).

Heat Shock Protein and Heat Shock Protein Antibody Levels
Hsp60 levels were markedly higher in the BHT group (P=0.001), whereas there was no significant difference in Hsp70 levels (Table 2). Hsp60 was present in all of the patients with BHT (100%) and 73 of the 75 control subjects (97%). Circulating Hsp70 was detectable in 36 of the 65 individuals with BHT (55%) and 37 of the 75 control subjects (49%).


View this table:
[in this window]
[in a new window]
 
Table 2. Serum Heat Shock Protein and Heat Shock Protein Antibody Levels in NT and BHT Subjects

Anti–human Hsp60, anti–human Hsp70, and anti–mycobacterial Hsp65 antibodies were detected in all of the BHT samples analyzed. Anti-Hsp60 antibodies were detected in all 75 of the control samples, but there were 10 individuals who were negative for anti–mycobacterial Hsp65 antibodies and 2 individuals who were negative for anti-Hsp70 antibodies. The anti–mycobacterial Hsp65 antibody levels were significantly higher in the BHT group (P<0.001; Table 2), which confirms previous findings in the same patient group.7 In contrast to anti-Hsp65 antibody levels, anti–human Hsp60 antibodies were significantly lower in the BHT group, although the differences were quantitatively small (P<0.03; Table 2). Anti-Hsp70 antibody levels in the BHT group were not different than those in NT subjects (Table 2).

Relationships Among Hsp, Anti-Hsp Antibodies, I/M Thickness, BP Levels, and Metabolic Variables
There were significant associations between Hsp60 and DBP (r=0.34, P<0.0001) and 24-hour systolic BP (SBP; r=0.179, P=0.037) in the complete study group. There also was a trend toward an association between Hsp60 and SBP and 24-hour DBP, but this was not of statistical significance. Furthermore, anti-Hsp65 antibody levels were associated with DBP (r=0.187, P=0.028) but not with SBP (r=0.146, P=0.087) or 24-hour DBP (r=0.159, P=0.07). There was no relationship between Hsp70 and anti-Hsp70 antibody levels with BP.

Given that DBP in subjects >60 years old plateaus and that there is an increasing relevance of SBP in subjects in that age group, data were also analyzed according to SBP of >140 mm Hg (n=39) or <140 mm Hg (n=106). The pattern was comparable to that observed when DBP was used. There was a trend for Hsp60 (P=0.072) and anti-Hsp65 (P=0.098) levels to be higher and anti-Hsp60 levels to be lower (P=0.023). Hsp70 and anti-Hsp70 levels did not differ significantly between patients and control subjects.

There was no significant association between heat shock proteins or heat shock protein antibody levels and BP parameters when the BHT and NT groups were analyzed separately.

I/M thickness was associated with Hsp60 levels in the entire group (I/M sin r=0.236, P=0.009; I/M dex r=0.255, P=0.004). This association was present in the BHT group alone (I/M sin r=0.236, P=0.009; I/M dex r=0.255, P=0.004) but not in the NT group. Hsp60 levels were higher in those individuals with carotid atherosclerosis than in those without (n=29; 4354±1885 versus 1885±702 ng/mL, mean±SEM), although this difference was not of statistical significance. However, there was a trend toward Hsp60 levels and atherosclerosis being associated in the BHT group (P=0.06).

Serum Hsp60 levels were associated with VLDL (P=0.017) and triglyceride (P=0.05) levels, but there was no association between Hsp70 or anti-heat shock protein antibody with blood lipids or metabolic factors, nor was there a significant associations between LDL and any of the heat shock protein–related parameters. There was no correlation between smoking status and any of the heat shock protein parameters measured (data not shown).

There was no difference in immunoglobulin levels between the BHT group and controls (IgG 9.71±1.9 versus 9.76±2.3 mg/mL, IgM 2.25±0.8 versus 2.1±0.9 mg/mL, respectively), thus excluding the possibility that differences in antibody levels simply reflected altered total antibody levels.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
In the present study, we identified enhanced levels of Hsp60 in the circulation of individuals with BHT. Hsp60 levels were associated with I/M thickness. Anti–human Hsp65 antibody levels were enhanced in BHT patients, whereas anti–human Hsp60 levels were slightly but significantly decreased.

The evidence for a heat shock protein–mediated component to atherosclerosis has arisen from a number of studies. The intensity of heat shock protein expression positively correlates with the severity of atherosclerosis, there is a localized enrichment of {gamma}/{delta} T cells in the lesion,20 and immunization with recombinant mycobacterial Hsp65 can induce atherosclerotic lesions in normocholesterolemic rabbits.21 Elevated levels of circulating antibody to the mycobacterial 65-kDa heat shock protein have been reported in carotid atherosclerosis5 and coronary heart disease.6 The in vivo physiological significance of heat shock protein antibodies in the pathogenesis of vascular disease has yet to be clearly established. However, they have been shown to mediate endothelial cell cytotoxicity,22 and the observation that anti-Hsp65/60 antibodies in individuals with atherosclerosis recognize 3 distinct, conserved sequences may implicate them in the initiation of atherosclerosis via an autoimmune type of mechanism.23

BHT is a condition that exhibits only minor cardiovascular changes, and the presence of circulating Hsp60 and anti–mycobacterial Hsp65 antibodies may reflect early vascular events. Raised BP has direct effects on the vasculature,24 25 and vessels subjected to greater mechanical and shear stress express heat shock proteins and are more prone to the development of atherosclerosis.20 22 25 26 In addition, Hsp70 mRNA levels are enhanced in hypertensive animals,27 28 and there is a greater accumulation of heat stress–induced Hsp70 mRNA in peripheral blood lymphocytes from hypertensive humans compared with that in NT control subjects.29 Although these findings demonstrate a stress response to hypertension, a definitive causative link between heat shock protein expression/release and the development of vascular disease has yet to be established.

It may be that the heat shock protein expression in the vasculature serves to protect against the effects of physiological and pathological insults such as mechanical stress, shear stress, hypercholesterolemia, free radicals, cytokines, and infections.30 The proposition has been that heat shock protein release is part of a response to protect neighboring cells,11 and this is supported by the observation that Hsp70 enhances the survival of stressed cultured arterial smooth muscle cells.31 32 However, it is possible that heat shock proteins potentiate later stages of atherogenesis by inducing heat shock protein antibodies,5 6 22 by the recruitment of heat shock protein–specific inflammatory lymphocyte populations,20 or by their expression on the endothelial cell surface.10

The putative involvement of heat shock proteins in the establishment and progression of the atherosclerotic lesion is undoubtedly complex. Heat shock protein expression may be secondary to the inflammatory process, in that the expression of cytokines by both the vascular endothelium and infiltrating leukocyte populations drives the expression or release of heat shock proteins from the vessel wall. Human atherosclerotic plaques express a spectrum of inflammatory cytokines, including interferon-{gamma}, interleukin-1{alpha} and -1ß, and tumor necrosis factor-{alpha},33 34 all of which have been shown to increase heat shock protein expression in a range of cell types.35 36 37 38 39 Alternatively, the localized expression of heat shock proteins may promote the production of cytokines, the enhanced expression of adhesion molecules, and the establishment and propagation of the inflammatory response. A number of studies lend support to this proposition. Bacterial and mycobacterial heat shock proteins induce proinflammatory cytokine expression,40 41 42 and bacterial heat shock proteins (DNAk and GroEL) induce intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression on human vascular endothelial cells.40 Chlamydial and human Hsp60 activate human vascular endothelial cells to express E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 and activate vascular endothelial cells, smooth muscle cells, and macrophages to secrete interleukin-6.43 Heat shock proteins may also be expressed by lipid-laden "foam" cells in the atherosclerotic plaque, in that in vitro exposure to oxidized LDL induces Hsp60 expression by monocytic cell lines39 and Hsp70 expression by human endothelial cells.44

This is the first report of increased circulating heat shock protein levels in BHT. Their nature and origin in normal and diseased states have yet to be identified, as have the mechanisms that underlie their release and the influence that released proteins exert on physiological processes. The relationship between circulating heat shock proteins and anti–heat shock protein antibodies is undoubtedly complex, and additional studies with an aim of characterizing the circulating protein, defining its relationship with serum antibody, and elucidating its physiological importance are clearly warranted.

Acknowledgments
This work was supported by the Swedish Medical Research Council, the Swedish Heart Lung Foundation, the King Gustav V 80th Birthday Fund, the Swedish Society of Medicine, and The Swedish Rheumatism Association. This study also received financial support from Vasogen Inc (Mississauga, Canada) and the UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR). We are grateful to Joey Shepherd for performing the heat shock protein immunoassays and to Ulla Hellmark for the blood pressure measurements. We are also grateful to Anders Hamsten for help with lipoprotein fractionation, Saud Efendic for help with insulin analysis, and Birger Andersson for help with analysis of total antibody levels.

Received October 21, 1999; first decision December 10, 1999; accepted February 17, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27–33.[Medline] [Order article via Infotrieve]

2. Kiessling R, Grönberg A, Ivanyi J, Söderström K, Ferm M, Kleinau S, Nilsson E, Klareskog L. Role of Hsp60 during autoimmune and bacterial inflammation. Immunol Rev. 1991;12:91–111.

3. Hightower LE. Heat shock, stress proteins, chaperones and proteotoxicity. Cell. 1991;66:191–197.[Medline] [Order article via Infotrieve]

4. Lamb JR, Bal V, Mendez-Samperio A, Mehlert A, So J, Rothbard JB, Jindal S, Young RA, Young DB. Stress proteins may provide a link between the immune response to infection and autoimmunity. Int Immunol. 1989;1:191–196.[Abstract/Free Full Text]

5. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, Stulnig T, Luef G, Wick G. Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lancet. 1993;341:255–259.[Medline] [Order article via Infotrieve]

6. Hoppichler F, Lechleitner M, Traweger C, Schett G, Dzien A, Sturm W, Xu Q. Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction. Atherosclerosis. 1996;126:333–338.[Medline] [Order article via Infotrieve]

7. Frostegård J, Lemne C, Andersson B, van der Zee R, Kiessling R, de Faire U. Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension. 1997;29:40–44.[Abstract/Free Full Text]

8. Wand-Wurttenberger A, Schoel B, Ivanyi J, Kaufmann SH. Surface expression by mononuclear phagocytes of an epitope shared with mycobacterial heat shock protein 60. Eur J Immunol. 1991;21:1089–1092.[Medline] [Order article via Infotrieve]

9. Di Cesare S, Poccia F, Mastino A, Colizzi V. Surface expressed heat-shock proteins by stressed or human immunodeficiency virus (HIV)-infected lymphoid cells represent the target for antibody-dependent cellular cytotoxicity. Immunology. 1992;76:341–343.[Medline] [Order article via Infotrieve]

10. Xu Q, Schett G, Seitz CS, Hu Y, Gupta RS, Wick G. Surface staining and cytotoxic activity of heat-shock protein 60 in stressed aortic endothelial cells. Circ Res. 1994;75:1078–1085.[Abstract/Free Full Text]

11. Hightower LE, Guidon PT. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J Cell Physiol. 1989;138:257–266.[Medline] [Order article via Infotrieve]

12. Child DF, Williams CP, Jones RP, Hudson PR, Jones M, Smith CJ. Heat shock protein studies in type 1 and type 2 diabetes and human islet cell culture. Diabetic Med. 1995;12:595–599.[Medline] [Order article via Infotrieve]

13. Pockley AG, Bulmer J, Hanks BM, Wright BH. Identification of human heat shock protein 60 (Hsp60) and anti-Hsp60 antibodies in the peripheral circulation of normal individuals. Cell Stress Chaperones. 1999;4:29–35.[Medline] [Order article via Infotrieve]

14. Pockley AG, Shepherd J, Corton J. Detection of heat shock protein 70 (Hsp70) and anti-Hsp70 antibodies in the serum of normal individuals. Immunol Invest. 1998;27:367–377.[Medline] [Order article via Infotrieve]

15. Lemne C, Jogestrand T, de Faire U. Carotid intima-media thickness and plaque in borderline hypertension. Stroke. 1995;26:34–39.[Abstract/Free Full Text]

16. Frostegård J, Wu R, Gillis-Haegerstrand C, Lemne C, de Faire U. Antibodies to endothelial cells in borderline hypertension. Circulation. 1998;98:1092–1098.[Abstract/Free Full Text]

17. Danieli MG, Candela M, Ricciatti AM, Reginelli R, Danieli G, Cohen IR, Gabrielli A. Antibodies to Mycobacterial 65 kDa heat shock protein in systemic sclerosis (scleroderma). J Autoimmunity. 1992;5:443–452.[Medline] [Order article via Infotrieve]

18. Carlsson K. Lipoprotein fractionation. J Clin Pathol. 1973;5(suppl 26):32–37.

19. Lemne C, Hamsten A, KKarpe F, Nilsson-Ehle P, de Faire U. Dyslipoproteinemic changes in borderline hypertension. Hypertension. 1994;24:605–610.[Abstract/Free Full Text]

20. Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, Wick G. Immunology of atherosclerosis: demonstration of hsp60 expression and T lymphocytes bearing {alpha}ß or {gamma}{delta} receptor in human atherosclerotic lesions. Am J Path. 1993;142:1927–1937.[Abstract]

21. Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz G, Kaufmann SH, Wick G. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb. 1992;12:789–799.[Abstract/Free Full Text]

22. Schett G, Xu Q, Amberger A, Van der Zee R, Reiches H, Willeit J, Wick G. Autoantibodies against heat shock protein mediate endothelial cytotoxicity. J Clin Invest. 1995;96:2569–2577.

23. Metzler B, Schett G, Kleindienst R, van der Zee R, Ottenhoff T, Hajeer A, Bernstein R, Xu Q, Wick G. Epitope specificity of anti-heat shock protein 65/60 serum antibodies in atherosclerosis. Arterioscler Throm Vasc Biol. 1997;17:536–541.[Abstract/Free Full Text]

24. Hollander W, Prusty S, Kemper T, Rosene DL, Moss MB. The effects of hypertension on cerebral atherosclerosis in the cynomolgus monkey. Stroke. 1993;24:1218–1226.[Abstract/Free Full Text]

25. Sawchuk AP, Unthank JL, Davis TE, Dalsing MC. A prospective, in vivo study of the relationship between blood flow haemodynamics and atherosclerosis in a hyperlipidemic swine model. J Vasc Surg. 1994;19:58–63.[Medline] [Order article via Infotrieve]

26. Solberg LA, Strong JP. Risk factors and atherosclerotic lesions: a review of autopsy studies. Arteriosclerosis. 1983;3:187–198.[Abstract/Free Full Text]

27. Malo D, Schlager G, Tremblay J, Hamet P. Thermosensitivity, a possible new locus involved in genetic hypertension. Hypertension. 1989;14:121–128.[Abstract/Free Full Text]

28. Hamet P, Kong D, Pravenec M, Kunes J, Kren V, Klir P, Yu-Lin S, Tremblay J. Restriction fragment length polymorphism of hsp70 gene, localized in the RT1 complex, is associated with hypertension in spontaneously hypertensive rats. Hypertension. 1992;19:611–614.[Free Full Text]

29. Kunes J, Poirier M, Tremblay J, Hamet P. Expression of hsp70 gene in lymphocytes from normotensive and hypertensive humans. Acta Physiol Scand. 1992;146:307–311.[Medline] [Order article via Infotrieve]

30. Xu G, Wick G. Stress proteins in atherogenesis. In: van Eden W, Young DB, eds. Stress Proteins in Medicine. New York, NY: Marcel Dekker; 1996:445–463.

31. Johnson AD, Berberian PA, Bond MG. Effect of heat shock proteins on survival of isolated aortic cells from normal and atherosclerotic cynomolgus macaques. Atherosclerosis. 1990;84:111–119.[Medline] [Order article via Infotrieve]

32. Johnson AD, Tytell M. Exogenous Hsp70 becomes cell associated, but not internalised by stressed arterial smooth muscle cells. In Vitro Cell Dev Biol. 1993;29A:807–812.

33. Hansson G. Immune responses in atherosclerosis. In: Hansson G, Libby P, eds. Immune Functions of the Vessel Wall. Amsterdam, the Netherlands: Harwood Academic Publishers GmbH; 1996:143–158.

34. Frostegård J, Ulfgren A-K, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33–43.[Medline] [Order article via Infotrieve]

35. Fincato G, Polentaurutti N, Sica A, Mantovab A, Collotti F. Expression of a heat inducible gene of the Hsp70 family in myelomonocytic cells: regulation by bacterial products and cytokines. Blood. 1991;77:579–586.[Abstract/Free Full Text]

36. Ferm MT, Söderström K, Jindal S, Grönberg A, Ivanyi J, Young R, Kiessling R. Induction of human Hsp60 expression in monocytic cell lines. Int Immunol. 1992;4:305–311.[Abstract/Free Full Text]

37. Low-Friedrich I, Weisensee D, Mitrou P, Schoeppe W. Cytokines induce stress protein formation in cultured cardiac myocytes. Basic Res Cardiol. 1992;87:12–18.[Medline] [Order article via Infotrieve]

38. D’Souza SD, Antel JP, Freedmen MS. Cytokine induction of heat shock protein expression in human oligodendrocytes: an interleukin-1-mediated mechanism. J Neuroimmunol. 1994;50:17–24.[Medline] [Order article via Infotrieve]

39. Frostegård J, Kjellman B, Gidlund M, Andersson B, Jindal S, Kiessling R. Induction of heat shock protein in monocytic cells by oxidised low density lipoprotein. Atherosclerosis. 1996;121:93–103.[Medline] [Order article via Infotrieve]

40. Galdiero M, de l’Ero GC, Marcatili A. Cytokine and adhesion molecule expression in human monocytes and endothelial cells stimulated with bacterial heat shock proteins. Infect Immun. 1997;65:699–707.[Abstract]

41. Retzlaff C, Yamamoto Y, Hoffman PS, Friedman H, Klein TW. Bacterial heat shock proteins directly induce cytokine mRNA and interleukin-1 secretion in macrophage cultures. Infect Immun. 1994;62:5689–5693.[Abstract/Free Full Text]

42. Peetermans WE, Raats CJ, Langermans JA, van Furth R. Mycobacterial heat shock protein 65 induces proinflammatory cytokines but does not activate human mononuclear phagocytes. Scand J Immunol. 1994;39:613–617.[Medline] [Order article via Infotrieve]

43. Kol A, Bourcier T, Lichtman A, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest. 1999;103:571–577.[Medline] [Order article via Infotrieve]

44. Zhu W, Roma P, Pellegatta F, Catapano AL. Oxidised-LDL induce the expression of heat shock protein 70 in human endothelial cells. Biochem Biophys Res Commun. 1994;200:389–394.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
CirculationHome page
X. Zhang, M. He, L. Cheng, Y. Chen, L. Zhou, H. Zeng, A. G. Pockley, F. B. Hu, and T. Wu
Elevated Heat Shock Protein 60 Levels Are Associated With Higher Risk of Coronary Heart Disease in Chinese
Circulation, December 16, 2008; 118(25): 2687 - 2693.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
X. Zhang, M.-A. He, L. Cheng, L. Zhou, H. Zeng, J. Wang, F. Wang, Y. Chen, F. B. Hu, and T. Wu
Joint Effects of Antibody to Heat Shock Protein 60, Hypertension, and Diabetes on Risk of Coronary Heart Disease in Chinese
Clin. Chem., June 1, 2008; 54(6): 1046 - 1052.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Gupta and A. A. Knowlton
HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3052 - H3056.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Shamaei-Tousi, J. P. Halcox, and B. Henderson
Stressing the obvious? Cell stress and cell stress proteins in cardiovascular disease
Cardiovasc Res, April 1, 2007; 74(1): 19 - 28.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
A. Steptoe, A. Shamaei-Tousi, A. Gylfe, L. Bailey, S. Bergstrom, A. R. Coates, and B. Henderson
Protective Effect of Human Heat Shock Protein 60 Suggested by Its Association with Decreased Seropositivity to Pathogens
Clin. Vaccine Immunol., February 1, 2007; 14(2): 204 - 207.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Wick
The Heat Is on: Heat-Shock Proteins and Atherosclerosis
Circulation, August 29, 2006; 114(9): 870 - 872.
[Full Text] [PDF]


Home page
Eur Heart JHome page
A. Shamaei-Tousi, J. W. Stephens, R. Bin, J. A. Cooper, A. Steptoe, A. R.M. Coates, B. Henderson, and S. E. Humphries
Association between plasma levels of heat shock protein 60 and cardiovascular disease in patients with diabetes mellitus
Eur. Heart J., July 1, 2006; 27(13): 1565 - 1570.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
L. Romics Jr, G. Szabo, J. C. Coffey, J. H. Wang, and H. P. Redmond
The Emerging Role of Toll-Like Receptor Pathways in Surgical Diseases
Arch Surg, June 1, 2006; 141(6): 595 - 601.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. Tedgui and Z. Mallat
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Physiol Rev, April 1, 2006; 86(2): 515 - 581.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S.-i. Yokota, S. Minota, and N. Fujii
Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors
Int. Immunol., April 1, 2006; 18(4): 573 - 580.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
S G Baidya and Q-T Zeng
Helper T cells and atherosclerosis: the cytokine web
Postgrad. Med. J., December 1, 2005; 81(962): 746 - 752.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
Q. Xiao, K. Mandal, G. Schett, M. Mayr, G. Wick, F. Oberhollenzer, J. Willeit, S. Kiechl, and Q. Xu
Association of Serum-Soluble Heat Shock Protein 60 With Carotid Atherosclerosis: Clinical Significance Determined in a Follow-Up Study
Stroke, December 1, 2005; 36(12): 2571 - 2576.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. P.J. Halcox, J. Deanfield, A. Shamaei-Tousi, B. Henderson, A. Steptoe, A. R.M. Coates, A. Singhal, and A. Lucas
Circulating Human Heat Shock Protein 60 in the Blood of Healthy Teenagers: A Novel Determinant of Endothelial Dysfunction and Early Vascular Injury?
Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): e141 - e142.
[Full Text] [PDF]


Home page
HeartHome page
A G Pockley and J Frostegard
Heat shock proteins in cardiovascular disease and the prognostic value of heat shock protein related measurements
Heart, September 1, 2005; 91(9): 1124 - 1126.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. A. Bausero, R. Gastpar, G. Multhoff, and A. Asea
Alternative Mechanism by which IFN-{gamma} Enhances Tumor Recognition: Active Release of Heat Shock Protein 72
J. Immunol., September 1, 2005; 175(5): 2900 - 2912.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Frostegard
Atherosclerosis in Patients With Autoimmune Disorders
Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1776 - 1785.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Foteinos, A. R. Afzal, K. Mandal, M. Jahangiri, and Q. Xu
Anti-Heat Shock Protein 60 Autoantibodies Induce Atherosclerosis in Apolipoprotein E-Deficient Mice via Endothelial Damage
Circulation, August 23, 2005; 112(8): 1206 - 1213.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
U. Hagg, M. E. Johansson, J. Gronros, A. S. Naylor, I. H. Jonsdottir, G. Bergstrom, P.-A. Svensson, and L.-m. Gan
Gene expression profile and aortic vessel distensibility in voluntarily exercised spontaneously hypertensive rats: potential role of heat shock proteins
Physiol Genomics, August 11, 2005; 22(3): 319 - 326.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Habich, K. Kempe, R. van der Zee, R. Rumenapf, H. Akiyama, H. Kolb, and V. Burkart
Heat Shock Protein 60: Specific Binding of Lipopolysaccharide
J. Immunol., February 1, 2005; 174(3): 1298 - 1305.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. L. Martin-Ventura, M. C. Duran, L. M. Blanco-Colio, O. Meilhac, A. Leclercq, J.-B. Michel, O. N. Jensen, S. Hernandez-Merida, J. Tunon, F. Vivanco, et al.
Identification by a Differential Proteomic Approach of Heat Shock Protein 27 as a Potential Marker of Atherosclerosis
Circulation, October 12, 2004; 110(15): 2216 - 2219.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
M.-F. Tsan and B. Gao
Cytokine function of heat shock proteins
Am J Physiol Cell Physiol, April 1, 2004; 286(4): C739 - C744.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Buhlin, A. Gustafsson, A.G. Pockley, J. Frostegard, and B. Klinge
Risk factors for cardiovascular disease in patients with periodontitis
Eur. Heart J., December 1, 2003; 24(23): 2099 - 2107.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. G. Pockley, A. Georgiades, T. Thulin, U. de Faire, and J. Frostegard
Serum Heat Shock Protein 70 Levels Predict the Development of Atherosclerosis in Subjects With Established Hypertension
Hypertension, September 1, 2003; 42(3): 235 - 238.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Gao and M.-F. Tsan
Recombinant Human Heat Shock Protein 60 Does Not Induce the Release of Tumor Necrosis Factor {alpha} from Murine Macrophages
J. Biol. Chem., June 13, 2003; 278(25): 22523 - 22529.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Zhu, A. A. Quyyumi, H. Wu, G. Csako, D. Rott, A. Zalles-Ganley, J. Ogunmakinwa, J. Halcox, and S. E. Epstein
Increased Serum Levels of Heat Shock Protein 70 Are Associated With Low Risk of Coronary Artery Disease
Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1055 - 1059.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Q. Xu
Role of Heat Shock Proteins in Atherosclerosis
Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1547 - 1559.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. G. Pockley
Heat Shock Proteins, Inflammation, and Cardiovascular Disease
Circulation, February 26, 2002; 105(8): 1012 - 1017.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. K. Hansson
Immune Mechanisms in Atherosclerosis
Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 1876 - 1890.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. K. Kanwar, J. R. Kanwar, D. Wang, D. J. Ormrod, and G. W. Krissansen
Temporal Expression of Heat Shock Proteins 60 and 70 at Lesion-Prone Sites During Atherogenesis in ApoE-Deficient Mice
Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 1991 - 1997.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. Dybdahl, A. Wahba, E. Lien, T. H. Flo, A. Waage, N. Qureshi, O. F.M. Sellevold, T. Espevik, and A. Sundan
Inflammatory Response After Open Heart Surgery: Release of Heat-Shock Protein 70 and Signaling Through Toll-Like Receptor-4
Circulation, February 12, 2002; 105(6): 685 - 690.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pockley, A. G.
Right arrow Articles by Frostegård, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pockley, A. G.
Right arrow Articles by Frostegård, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Pathophysiology
Right arrow Other hypertension
Right arrow Other arteriosclerosis
Right arrow Mechanism of atherosclerosis/growth factors
Right arrow Other Vascular biology
Right arrow Other Research